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Abstract
Introduction  PTPN22,  PADI-4, and CTLA-4  have been
associated with risk for rheumatoid arthritis (RA). We
investigated whether polymorphisms in these genes were
associated with RA in Caucasian women included in two large
prospective cohorts, adjusting for confounding factors and
testing for interactions with smoking.
Methods We studied RA risk associated with PTPN22
(rs2476601), PADI-4 (rs2240340), and CTLA-4 (rs3087243)
in the Nurses' Health Study (NHS) and NHSII. Participants in
NHS were aged 30 to 55 years at entry in 1976; those in NHSII
were aged 25 to 42 years at entry in 1989. We confirmed
incident RA cases through to 2002 in NHS and to 2003 in
NHSII by questionnaire and medical record review. We
excluded reports not confirmed as RA. In a nested case-control
design involving participants for whom there were samples for
genetic analyses (45% of NHS and 25% of NHSII), each
incident RA case was matched to a participant without RA by
year of birth, menopausal status, and postmenopausal hormone
use. Genotyping was performed using Taqman single
nucleotide polymorphism allelic discrimination on the ABI 7900
HT (Applied Biosystems, 850 Lincoln Centre Drive, Foster City,
CA 94404 USA) with published primers. Human leukocyte
antigen shared epitope (HLA-SE) genotyping was performed at
high resolution. We employed conditional logistic regression
analyses, adjusting for smoking and reproductive factors. We
tested for additive and multiplicative interactions between each
genotype and smoking.
Results A total of 437 incident RA cases were matched to
healthy female control individuals. Mean (± standard deviation)
age at RA diagnosis was 55 (± 10), 57% of RA cases were
rheumatoid factor (RF) positive, and 31% had radiographic
erosions at diagnosis. PTPN22 was associated with increased
RA risk (pooled odds ratio in multivariable dominant model =
1.46, 95% confidence interval [CI] = 1.02 to 2.08). The risk was
stronger for RF-positive than for RF-negative RA. A significant
multiplicative interaction between PTPN22  and smoking for
more than 10 pack-years was observed (P = 0.04). CTLA-4 and
PADI-4  genotypes were not associated with RA risk in the
pooled results (pooled odds ratios in multivariable dominant
models: 1.27 [95% CI = 0.88 to 1.84] for CTLA-4 and 1.04
[95% CI = 0.77 to 1.40] for PADI-4). No gene-gene interaction
was observed between PTPN22 and HLA-SE.
Conclusion After adjusting for smoking and reproductive
factors, PTPN22 was associated with RA risk among Caucasian
women in these cohorts. We found both additive and
multiplicative interactions between PTPN22 and heavy cigarette
smoking.
ACR = American College of Rheumatology; CCP = cyclic citrullinated peptide; CI = confidence interval; HLA = human leukocyte antigen; NHS = 
Nurses' Health Study; OR = odds ratio; RA = rheumatoid arthritis; RF = rheumatoid factor; SE = shared epitope; SNP = single nucleotide polymor-
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
that is characterized by chronic, destructive, and debilitating
arthritis. The most common inflammatory arthritis, it affects
approximately 1% of the population [1]. The etiology of RA is
unknown, but it is presumed that environmental factors trigger
its development in the genetically predisposed. The strongest
genetic risk factor, which is responsible for approximately 30%
of the genetic contribution to the development of RA, is human
leukocyte antigen (HLA) type [2,3]. The HLA-shared epitope
(SE) is the strongest known genetic risk factor for RA, with two
copies associated with a relative risk of 5 to 6 in Caucasians
[4-6]. However, RA, like many complex human diseases, is
polygenic in origin. It is likely that many other genes, both
inside and outside the HLA region, contribute to disease pre-
disposition [5,7-10]. RA genetic studies have reported poly-
morphisms PTPN22 (R620W, rs2476601) [9,11-16], CTLA-
4  (CT60, rs3087243) [17,18], and PADI-4  (PADI4_94,
rs2240340) [8] to be associated with increased risk for RA.
More recently, polymorphisms in or near the genes encoding
STAT4 [19], TRAF1-C5 [20], TNF-AIP2 [16], and IL2RA [16]
have been reported in whole-genome scans. The non-HLA
genetic polymorphism that has been most strongly replicated
across multiple independent studies is PTPN22  [9,11-
14,16,21-24]. This missense allele (C→T) has been associ-
ated in past studies with an odds ratio (OR) for RA of approx-
imately 1.8 [9], and it appears to carry greater risk for
autoantibody-positive RA [12,24,25]. Homozygotes for the
variant T allele are at greatest risk for RA (OR = 4.6) [12]. This
polymorphism has also been associated with increased risk for
type I diabetes [26,27] and systemic lupus erythematosus
[11,13]. The associations of CTLA-4 and PADI-4 polymor-
phisms with RA risk have been less well replicated [17,18,28].
In a large pooled replication study, CTLA4 CT60 polymor-
phism was associated with anti-cyclic citrullinated peptide
antibody (anti-CCP)-positive RA [25].
Twin studies conducted in the UK and Finland have estimated
that 50% to 60% of the variation in RA susceptibility is
accounted for by genetic factors [29], leaving 40% to 50%
probably due to environmental exposures. Cigarette smoking
is the best established environmental risk factor for RA, with
risk increasing in proportion to duration and intensity of expo-
sure [30-35]. Case-control studies conducted in Sweden,
Holland, and North America have identified an interaction
between presence of the HLA-SE alleles and cigarette smok-
ing in determining RA risk, in particular that of anti-CCP-posi-
tive RA [36-38]. Female reproductive factors such as early age
at menarche, irregular menses, and use of postmenopausal
hormones have also been related to increased RA risk, and
prolonged duration of breast-feeding was found to be protec-
tive against development of RA in the Nurses' Health Study
(NHS) [39-41].
We aimed to validate previous findings of increased risk for RA
associated with polymorphisms in the PTPN22, PADI-4 and
CTLA-4  genes, and to assess whether of behavioral and
reproductive factors that are known to be associated with RA
risk influence these findings. We also investigated potential
additive and multiplicative interactions between each of these
polymorphisms and the presence of the HLA-SE. To do this,
we conducted a case-control study nested within the NHS
and NHSII; those studies include two large cohorts of women,
who were followed closely over many years for behavioral and
reproductive factors before the onset of disease.
Materials and methods
Study population
The NHS includes a prospective cohort of 121,700 female
nurses, aged 30 to 55 years in 1976 when the study began.
The NHSII was established in 1989, when 116,608 female
nurses aged 25 to 42 years completed a baseline question-
naire about their medical histories and lifestyles. Ninety-four
per cent of the NHS participants from 1976 to 2002, and 95%
of NHSII participants from 1989 to 2003 have remained in
active follow up (5% to 6% no longer respond to question-
naires and have not been confirmed as dead). All aspects of
this study were approved by the Partners' HealthCare Institu-
tional Review Board.
Identification of rheumatoid arthritis
As previously described [35], we employed a two-stage pro-
cedure in which all nurses who self-reported any connective
tissue disease received a screening questionnaire for connec-
tive tissue disease symptoms [42], and – if positive – a
detailed medical record review for American College of Rheu-
matology (ACR) classification criteria for RA [43], in order to
identify and validate incident cases of RA. The presence or
absence of rheumatoid factor (RF) and other features of RA
was based on medical record review. Those in whom four of
the seven ACR criteria were documented in the medical
record were considered to have definite RA. For this nested
case-control study, we also included a small number of women
(n = 14) with three documented ACR criteria for RA, a diagno-
sis of RA by their physician, and agreement by two rheumatol-
ogists on the diagnosis of RA.
Population for analysis
We excluded prevalent RA cases diagnosed before the cohort
was assembled, nonresponders, and women who reported
any connective tissue disease that was not subsequently con-
firmed to be RA by medical record review. Women were cen-
sored when they failed to respond to any subsequent biennial
questionnaires. Among the women in each cohort who had
provided a sample for genetic analyses, each participant with
confirmed incident RA was matched by year of birth, meno-
pausal status, and postmenopausal hormone use to a healthy
woman in the same cohort without RA. To minimize population
stratification, and given that most cohort participants are Cau-Available online http://arthritis-research.com/content/10/3/R52
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casian, we limited the analyses to Caucasian matched pairs of
women. In 1992 (NHS) and 1989 (NHSII), all participants
were asked to provide data concerning their own racial back-
grounds in more detailed categories. Of the Caucasian
women in NHS and NHSII included in this analysis, 2%
reported pure Scandinavian heritage, 15% reported pure
Southern European, and 83% reported other or mixed Cauca-
sian backgrounds. There were no significant differences in the
distributions of these ethnicities between cases and controls
(χ2 with two degrees of freedom, P = 0.30).
Blood sampling
From 1989 to 1990, 32,826 (27%) NHS participants aged 43
to 70 years agreed to provide blood samples for future NHS
studies. Between 1996 and 1999, 29,613 (25%) of the
women included in the NHSII cohort (aged 32 to 52 years at
that time) also agreed to have their blood drawn for future
investigations. All samples were collected in heparinized tubes
and sent to us by overnight courier in chilled containers. On
receipt, the blood samples were centrifuged, aliquoted, and
stored in liquid nitrogen freezers at -70°F (-57°C). The demo-
graphic and exposure characteristics of the NHS and NHSII
participants who provided blood samples were found to be
very similar to those of the overall cohorts [44,45].
DNA extraction from blood
DNA was extracted from buffy coats from 96 samples in 3 to
4 hours. A volume of 50 μl of buffy coat was diluted with 150
μl phosphate-buffered saline and processed using the
QIAmp™ (QIAGEN Inc., Chatsworth, CA, USA) 96-spin blood
kit protocol. The protocol entails adding protease, the sample,
and lysis buffer to 96-well plates. The plates are then mixed
and incubated at 158°F (70°C), before adding ethanol and
transferring the samples to columned plates. The columned
plates are then centrifuged and washed with buffer. Adding
elution buffer and centrifuging elutes the DNA. The average
yield from 50 μl of buffy coat (based on 1,000 samples) is 5.5
μg with a standard deviation of 2.2 (range 2.0 to 16.4). These
methods are semiautomated using a Qiagen 8000 robot to
increase throughput and decrease manual pipetting errors.
Buccal cell collection method and DNA extraction in NHS
Forty thousand women in NHS who did not give blood in 1989
to 1990 were asked to give a buccal cell sample in 2002. To
date we have collected an additional 21,733 buccal cell sam-
ples (18% of the NHS cohort). A collection kit was sent to par-
ticipants, consisting of instructions for the buccal cell
collection and the necessary supplies (a small bottle of mouth-
wash, a plastic cup with a screwtop cap, a ziplock plastic bag
and absorbent sheet, and a stamped, self-addressed bubble
envelope), as well as an informed consent form. Participants
were instructed to fill the cup with mouthwash, swish the
mouthwash in their mouth vigorously, and then spit back into
the cup. Returned samples were processed using ReturPure-
Gene DNA Isolation Kit (Gentra Systems, Minneapolis, MN,
USA) to extract genomic DNA from human cheek cells. The
extracted DNA was archived in liquid nitrogen freezers using
specific tracking software. The average DNA recovery from
these specimens measured using PicoGreen was 59 ng/μl.
Whole-genome amplification
For all genomic DNA samples, an aliquot was put through a
whole-genome amplification protocol using the GenomPhi
DNA amplification kit (GE Healthcare, Piscataway, NJ) to yield
high-quality DNA sufficient for single nucleotide polymorphism
(SNP) genotyping.
Single nucleotide polymorphism genotyping
DNA was genotyped using Taqman SNP allelic discrimination
on the ABI 7900 HT (Applied Biosystems, 850 Lincoln Centre
Drive, Foster City, CA 94404 USA) using published primers
[8,9,18,46]. We studied only the CTLA-4 CT60 (rs3087243)
allele. We chose the PADI4_94 allele (rs2240340) of the hap-
lotype first described by Suzuki and coworkers [8], because it
had the strongest association in a Japanese population and
was replicated in a large meta-analysis [25]. Using the same
methods, we also genotyped the lactase gene (rs4988235),
which is known to exhibit substantial variation in allele fre-
quency from Northern to Southern Europe, in order to test for
population stratification in this nested case-control study
[47,48].
HLA-DRB1 shared epitope determination
Low-resolution HLA-DRB1 genotyping was performed by
polymerase chain reaction with sequence specific primers
using OLERUP SSP kits (QIAGEN, West Chester, PA, USA).
We used primers to amplify DNA samples that contained
sequences for HLA-DRB1*04, *01,*10 and *14, along with
consensus primers and appropriate positive and negative con-
trol samples. For samples with positive two-digit HLA signals,
sequence-specific primers were used for high resolution four-
digit shared epitope allele detection of DRB1*0401, *0404,
*0405, *0101, *0102, *1402, and *1001. OLERUP SSP com-
puter software (QIAGEN) was used to determine four-digit
HLA types. Quality control split samples were included, ran-
domly interspersed with study samples.
Covariate information
Information was collected from the women in both cohorts via
biennial questionnaires regarding diseases, lifestyle, and
health practices. Age was updated in each cycle. Reproduc-
tive covariates were chosen based on our past findings of
associations between reproductive factors and risk for devel-
oping RA in this cohort [41]. Data on parity, total duration of
breast-feeding, menopausal status, and postmenopausal hor-
mone use were selected from the questionnaire cycle before
the date of RA diagnosis (or index date in controls). Self-
reported menopausal status and age at menopause are highly
reproducible in our cohorts; in a validation study of a subsam-
ple of NHS participants, 82% of naturally postmenopausalArthritis Research & Therapy    Vol 10 No 3    Costenbader et al.
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women reported the same age at menopause (within 1 year)
on two questionnaires mailed 2 years apart [49].
Participants in both cohorts were asked at baseline whether
they were a current smoker or had ever smoked in the past and
the age at which they began to smoke. Current smokers were
asked for the number of cigarettes typically smoked per day
and former smokers reported the age at which they stopped
smoking and the number of cigarettes smoked per day before
quitting. On each subsequent questionnaire, participants
reported whether they currently smoked and the number of
cigarettes smoked per day. From these reports, we calculated
pack years of smoking (product of years of smoking and packs
of cigarettes per day).
Other potential confounders examined included, body mass
index, which was computed for each 2-year time interval using
the most recent weight (in kilograms) divided by height (in
meters squared), as reported at baseline. Alcohol intake was
reported at least every 4 years and categorized in grams per
day. Husband's educational level was assessed in 1992 in
NHS and 1999 in NHSII, and was included as a proxy for soci-
oeconomic level.
Statistical analyses
We verified Hardy-Weinberg equilibrium for each of the geno-
types among controls in each of the datasets (NHS blood,
NHS cheek cells, and NHSII blood). We employed conditional
logistic regression analyses, conditioned on matching factors,
and adjusted for potential confounders, including cigarette
smoking and reproductive factors assessed before diagnosis
of RA. All analyses were first conducted separately in each
cohort and then on data pooled from the two cohorts.
Because the P value for heterogeneity was significant for the
CTLA-4 genotype, we also meta-analytically pooled results
from the two cohorts using a DerSimonian and Laird random
effects model [50]. In analyses stratified by the presence of RF
among the RA cases, we employed unconditional logistic
regression analyses, adjusting for each of the matching fac-
tors, in addition to the covariates above. For analyses of
PTPN22, we employed a dominant model because the minor
allele frequencies were low (9% in controls and 14% in
cases). In analyses involving CTLA-4  and  PADI-4, we
assessed the risk for RA in dominant, additive, and recessive
models.
Gene-environment and gene-gene interactions
We conducted assessments for gene-environment interac-
tions by testing for both additive and multiplicative interac-
tions. For additive interactions, we calculated the attributable
proportion due to interaction using a 2 × 2 factorial design to
analyze the data [51-53]. (There is evidence of interaction
when the attributable proportion is not equal to 0.) Ninety-five
per cent confidence intervals (CIs) were calculated using the
delta method as described by Hosmer and Lemeshow [54].
We tested for multiplicative interaction using an interaction
variable (for example, gene × smoking) in the conditional logis-
tic regression models. The significance of the interaction was
determined using the Wald χ2 test of the interaction variable.
In the combined NHS-NHSII nested case-control study data-
set, we assessed for interactions between the presence of
each polymorphism and cigarette smoking categorized both
as ever/never, and then dichotomized as ≤10 or ≥10 pack-
years of smoking, because this is the threshold we previously
identified to be associated with increased risk for RA [35].
Using similar methods, we tested for gene-gene interaction
between PTPN22 and HLA-SE in influencing RA susceptibil-
ity in analyses limited to NHS and NHSII blood samples. SAS
version 9.1 (SAS Institute, Cary, NC, USA) was used for all
analyses.
Results
A total of 437 pairs of Caucasian women, each containing one
woman with incident RA and her matched control, were
included in these analyses, after removing 18 women because
of missing data for all genotypes examined. The characteristics
of the RA cases at diagnosis in each of the two cohorts are
shown in Table 1. The cases in the NHS had a mean (± stand-
ard deviation) age of 57 years (± 9), as compared with 43 (±
5) in the younger NHSII cohort, because of the different ages
targeted for enrollment in the two cohorts. Otherwise, the
cases were similar in terms of the prevalence of RF, erosions,
nodules, and proportion diagnosed by a member of the ACR.
All cases and controls in these analyses were Caucasian, and
the mean (± standard deviation) number of ACR criteria for the
classification of RA was 5 (± 1) [43].
Table 2 shows the characteristics of the RA cases and
matched controls at the time of RA diagnosis (or index date for
the controls). A higher proportion of RA cases and controls
were postmenopausal at RA diagnosis in the NHS than in the
NHSII cohort, but the proportions of premenopausal and post-
menopausal women among cases and controls were similar in
each of the cohorts, as were the proportions currently receiv-
ing postmenopausal hormones. In NHSII a slightly higher per-
centage of women with RA were parous as compared with
their matched controls (94% and 86%), but this was not true
in the NHS cohort (91% of RA cases and 95% of controls).
Among women in the NHSII with RA, a higher proportion had
husbands who were college educated as compared with their
matched controls (39% compared to 18%), but this was not
true in the NHS cohort (20% in each group). No significant dif-
ferences in allele frequencies of the lactase gene (rs4988235)
in cases compared with controls were found. This argues
strongly against any significant population stratification in our
samples.
The genotype and allele frequencies of the RA cases and con-
trols for the three candidate genotypes are shown in Table 3.
None of the PTPN22, CTLA-4, or PADI-4 genotype distribu-Available online http://arthritis-research.com/content/10/3/R52
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tions deviated from Hardy-Weinberg equilibrium, either in
each cohort or in the combined dataset. Overall, genotyping
call rates were 97.5% for PTPN22, 96.4% for CTLA-4, 97.9%
for PADI-4, and 98.7% for HLA-SE. The frequency of the T
allele of the PTPN22 polymorphism was significantly higher
among RA cases than among controls (χ2 with one degree of
freedom, P = 0.001 for pooled NHS and NHSII cohorts). The
mutant alleles were not statistically associated with RA case
status for the other two genotypes, namely PADI-4 and CTLA-
4. As expected, HLA-SE alleles were highly significantly asso-
ciated with risk for RA. (A slightly higher frequency of NHS
cheek cell DNA samples could not be HLA genotyped: 3% of
cases and controls, as compared with 0% to 2% of NHS and
NHSII case and control DNA samples from blood.)
Table 4 includes the results of conditional logistic regression
analyses of risk for RA associated with each of the genotypes,
performed separately in each cohort, and then on pooled data.
The final multivariable model includes pack-years of cigarette
smoking, age at menarche, regularity of menses, parity, and
total duration of breast-feeding. Further adjustment for body
mass index, alcohol intake, husband's educational level, and
Table 1
Characteristics of RA cases at diagnosis of RA
Characteristic NHS (n = 388) NHSII (n = 49)
Age at diagnosis (mean ± SD) 57 ± 9 43 ± 5
Rheumatoid factor positive (n [%]) 223 (57%) 27 (55%)
Rheumatoid nodules (n [%]) 51 (13%) 6 (12%)
Radiographic changes (n [%]) 117 (30%) 17 (35%)
Diagnosed by a member of ACR (n [%]) 320(84%) 47 (96%)
Mean number of ACR criteria for RA [44], (SD) 5 ± 1 5 ± 1
ACR, American College of Rheumatology; NHS, Nurses' Health Study; RA, rheumatoid arthritis; SD, standard deviation.
Table 2
Characteristics of RA cases and matched controls: Caucasian matched pairs
Characteristics NHS (388 matched pairs) NHSII (49 matched pairs)
RA cases Controls RA cases Controls
Matching factors
Age (years; mean ± SD) 57 ± 9 57 ± 9 43 ± 5 43 ± 5
Postmenopausal (n [%]) 263 (68%) 255 (66%) 14 (29%) 14 (29%)
Current PMH use (n [%])a 111 (36%) 101 (34%) 11 (69%) 12 (75%)
Other characteristics
Ever cigarette smokers (n [%]) 246 (63%) 220 (57%) 19 (39%) 22 (45%)
Pack-years among smokers, mean (SD) 24 ± 17 24 ± 20 16 ± 9 11 ± 6
Parous (n [%]) 352 (91%) 367 (95%) 46 (94%) 42 (86%)
Breastfed babies ≥ 12 months total, among parous (n [%])a 44 (13%) 65 (18%) 18 (43%) 18 (45%)
Age at menarche <12 years (n [%]) 87 (22%) 77 (20%) 16 (33%) 15 (31%)
Irregular menstrual cycle (n [%]) 55 (14%) 49 (13%) 9 (18%) 11 (22%)
Husband education > college graduate (n [%]) 77 (20%) 77 (20%) 19 (39%) 9 (18%)
Physical activity (hours/day mean ± SD) 2 ± 3 2 ± 5 2 ± 3 3 ± 3
Alcohol intake (g/day; mean ± SD) 6 ± 10 6 ± 9 2 ± 1 2 ± 2
Body mass index (kg/m2; mean ± SD) 25 ± 4 26 ± 5 27 ± 7 26 ± 5
aPercentage is calculated among postmenopausal women or parous women, with unknown/missing group excluded. For the rest of variables, 
percentage was calculated with missing category included as a separate category. NHS, Nurses' Health Study; PMH, postmenopausal hormone; 
RA, rheumatoid arthritis; SD, standard deviation.Arthritis Research & Therapy    Vol 10 No 3    Costenbader et al.
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Table 3
Genotype and allele frequencies of the RA cases and controls for the three candidate genotypes (PTPN22, CTLA-4, and PADI-4) and 
genotype frequencies of HLA-SE
Gene Genotype/allele NHS blood (219 matched pairs) NHS cheek cell (169 matched pairs) NHSII blood (49 matched pairs)
Cases Controls Cases Controls Cases Controls
PTPN22a Genotype
CC 160 (74%) 178 (82%) 125 (77%) 131 (80%) 37 (79%) 44 (94%)
CT 50 (23%) 38 (18%) 30 (18%) 31 (19%) 7 (15%) 3 (6%)
TT 5 (2%) 1 (0.5%) 8 (5%) 1 (1%) 3 (6%) 0 (0%)
Missing 4 2 6 6 2 2
Pe 0.08 0.07 0.06
Allele
C 370 (86%) 394 (91%) 280 (86%) 293 (90%) 81 (86%) 91 (97%)
T 60 (14%) 40 (9%) 46 (14%) 33 (10%) 13 (14%) 3 (3%)
Pf 0.03 0.12 0.009
CTLA-4b Genotype
AA 35 (17%) 46 (22%) 40 (25%) 29 (18%) 7 (15%) 12 (25%)
AG 106 (50%) 96 (45%) 69 (42%) 80 (50%) 26 (54%) 19 (40%)
GG 71 (33%) 70 (33%) 54 (33%) 51 (32%) 15 (31%) 17 (35%)
Missing 7 7 6 9 1 1
Pf 0.37 0.27 0.28
Allele
A 176 (42%) 188 (44%) 149 (46%) 138 (43%) 40 (42%) 43 (45%)
G 248 (58%) 236 (56%) 177 (54%) 182 (57%) 56 (58%) 53 (55%)
Pf 0.41 0.51 0.66
PADI-4c Genotype
GG 76 (35%) 76 (36%) 57 (35%) 64 (39%) 22 (45%) 18 (38%)
GA 107 (49%) 101 (47%) 68 (41%) 73 (44%) 16 (33%) 21 (45%)
AA 34 (16%) 37 (17%) 39 (24%) 28 (17%) 11 (22%) 8 (17%)
Missing 2 5 5 4 0 2
Pf 0.87 0.30 0.47
Allele
G 259 (60%) 253 (59%) 182 (55%) 201 (61%) 60 (61%) 57 (61%)
A 175 (40%) 175 (41%) 146 (45%) 129 (39%) 38 (39%) 37 (39%)
Pf 0.87 0.16 0.93
HLA-SEd 0 copy 84 (38%) 122 (56%) 99 (60%) 114 (70%) 23 (47%) 30 (63%)
1 copies 99 (45%) 83 (38%) 52 (32%) 40 (24%) 17 (35%) 17 (35%)
2 copies 36 (16%) 14 (6%) 13 (8%) 10 (6%) 9 (18%) 1 (2%)
Missing 0 0 5 5 0 1
Pf 0.0001 0.22 0.03
aUnable to genotype 12 cases and 10 controls. bUnable to genotype 14 cases and 17 controls. cUnable to genotype 7 cases and 11 controls. 
dUnable to genotype 5 cases and 5 controls. eP values estimated from the Fisher's exact test. fP values estimated from the χ2 test. NHS, Nurses' 
Health Study; RA, rheumatoid arthritis. OKAvailable online http://arthritis-research.com/content/10/3/R52
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oral contraceptive use did not affect risk estimates either and
these were not included in the final models. As is evident com-
paring the results of a model taking only the matching factors
into account, adjustment for potential confounders did not sig-
nificantly influence results. The risk for RA associated with the
PTPN22 variant T allele was elevated (OR = 1.46 [95% CI =
1.02 to 2.08] in a NHS and NHSII pooled multivariable domi-
nant model). These results may have been influenced by the
high OR observed in the smaller NHSII cohort (OR = 8.77).
The CTLA-4 variant G allele was associated with an increased
RA risk among women in the NHS cohort (multivariable domi-
nant model OR = 1.92 [95% CI = 1.10 to 3.35]), but not in
the NHSII cohort or pooled results (multivariable dominant
model OR = 1.27 [95% CI = 0.88 to 1.84]; the OR was similar
[1.29, 95% CI = 0.54 to 3.08] in a random effects meta-ana-
lytically pooled dominant model). The PADI-4 genotype was
not associated with risk for RA in the NHS and NHSII cohorts
in any of the models.
To pursue potential associations of these polymorphisms with
different RA phenotypes, we conducted analyses stratified by
RF positivity, because many risk factors, including HLA-SE
and cigarette smoking, have been shown to be more strongly
associated with RF-seropositive RA [35,36]. Results of these
analyses are shown in Table 5. The effect of the PTPN22 pol-
ymorphism was seen primarily for the development of RF-sero-
positive RA (OR = 1.75 [95% CI = 1.18 to 2.59]).
Cigarette smoking is a strong environmental risk factor for the
development of RA, in particular RF-positive RA, and amount
and duration are associated with increased risk [35]. We thus
investigated potential interactions between the three polymor-
phisms of interest and the amount and duration of cigarette
Table 4
Effect of PTPN22, CTLA-4, and PADI-4 genotypes and the risk of RA in NHS, NHSII and pooled Caucasian matched pairs
Gene Model Genotype NHS blood NHS cheek NHSII blood NHS and NHSII pooled
ORa (95% CI) ORa (95% CI) ORa (95% CI) ORb (95% CI) ORa (95% CI) P for 
heterogeneityc
PTPN22d Dominant CC 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
CT/TT 1.59
(0.96–2.64)
1.10 
(0.62–1.96)
8.77 
(1.11–69.51)
1.47 
(1.05–2.05)
1.46 
(1.02–2.08)
0.14
CTLA-4 Dominant AA 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
AG/GG 1.92 
(1.10–3.35)
0.61 
(0.32–1.15)
2.18 
(0.65–7.38)
1.12 
(0.79–1.58)
1.27 
(0.88–1.84)
0.02
Additive AA 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
AG 1.98 
(1.09–3.59)
0.52 
(0.26–1.04)
2.43 
(0.68–8.67)
1.09 
(0.76–1.58)
1.24 
(0.84–1.84)
0.01
GG 1.85 
(1.00–3.41)
0.82 
(0.38–1.77)
1.71
 (0.40–7.31)
1.15 
(0.78–1.70)
1.31 
(0.86–1.99)
0.26
Recessive AA/AG 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
GG 1.13
 (0.74–1.74)
1.31 
(0.73–2.37)
0.89 
(0.30–2.63)
1.08 
(0.81–1.44)
1.12 
(0.83–1.52)
0.82
PADI-4 Dominant GG 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
GA/AA 1.10
 (0.71–1.71)
1.13 (0.69–1.86) 0.48 
(0.15–1.58)
1.02 
(0.77–1.35)
1.04 
(0.77–1.40)
0.41
Additive GG 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
GA 1.11 
(0.70–1.75)
0.89 (0.51–1.55) 0.19 
(0.04–1.03)
0.97 
(0.72–1.32)
0.96 
(0.70–1.33)
0.14
AA 1.07 
(0.56–2.05)
1.72 (0.88–3.36) 1.07 
(0.23–4.89)
1.14 
(0.77–1.68)
1.24 
(0.82–1.89)
0.58
Recessive GG/GA 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
AA 1.00
 (0.56–1.77)
1.82 (0.98–3.38) 1.51 
(0.38–5.96)
1.16 
(0.81–1.65)
1.27
 (0.87–1.86)
0.37
aConditional logistic regression, adjusting for pack-year smoking, parity, breast-feeding, menstrual irregularity, and age at menarche. bConditional 
logistic regression. cP for heterogeneity was calculated using multivariable model a for each cohort. dA dominant model only was tested for the 
PTPN22 genotype given a low homozygous risk genotype of 2%. CI, confidence interval; NHS, Nurses' Health Study; OR, odds ratio; RA, 
rheumatoid arthritis.Arthritis Research & Therapy    Vol 10 No 3    Costenbader et al.
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smoking at the time of RA diagnosis. Table 6 presents the
results of analyses in which we tested for both multiplicative
and additive interactions between smoking, categorized as
ever/never smoking and then dichotomized as ≤10 or ≥10
pack-years of smoking, for each of the genotypes. Among
those with the CC genotype of PTPN22, a modest effect of
heavy smoking was observed (OR = 1.22 [95% CI = 0.81 to
1.83). However, among those with the PTPN22 T risk allele,
the effect of heavy smoking was much more pronounced (OR
= 2.50 [95% CI = 1.25 to 5.00]). We observed significant
additive and multiplicative gene-environment interactions
between heavy cigarette smoking and the presence of the
PTPN22 T allele (additive interaction: P = 0.0006; multiplica-
tive interaction: P = 0.04). When smoking was dichotomized
as never/ever, there was marginal evidence for additive but not
multiplicative interaction. We also tested for genotype-smok-
ing interactions in RF-positive and RF-negative RA cases sep-
arately. In stratified analyses, we found significant additive but
not multiplicative interactions between the PTPN22 risk allele
and heavy smoking for both seropositive and seronegative RA.
We did not observe similar gene-smoking interactions for
CTLA-4 or PADI-4, for the overall risk for RA, or for RF-posi-
tive or RF-negative RA separately. No additive or multiplicative
interactions were observed between PTPN22 and HLA-SE
(Table 7). (Given potential difficulties with HLA-SE genotyping
Table 5
Stratified analyses of genotype and RA risk in the pooled NHS/
NHSII samples
Gene/genotype RF status of RA cases (versus controls)
RF-positive cases RF-negative cases
PTPN22
CC 1.00 (ref.) 1.00 (ref.)
CT/TT 1.75 (1.18–2.59) 1.32 (0.85–2.06)
CTLA-4
AA 1.00 (ref.) 1.00 (ref.)
AG/GG 1.18 (0.78–1.80) 1.11 (0.71–1.72)
PADI-4
GG 1.00 (ref.) 1.00 (ref.)
GA/AA 1.10 (0.79–1.54) 0.96 (0.66–1.38)
The analysis was unconditional logistic regression adjusting for year 
of birth, pack-year smoking, parity, breast-feeding, menstrual 
irregularity, age at menarche, menopausal status and 
postmenopausal hormone use. Values are expressed as odds ratio 
(95% confidence interval). CI, confidence interval; NHS, Nurses' 
Health Study; OR, odds ratio; RA, rheumatoid arthritis; RF, 
rheumatoid factor.
Table 6
PTPN22 genotype and smoking interactions according to RF status in NHS/NHSII pooled samples
Smoking status/pack-years PTPN22 Genotype All casesa RF-positive casesb,c RF-negative casesb,d
Smoking status
Never CC 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
Ever CC 1.10 (0.79–1.53) 1.37 (0.93–2.01) 1.02 (0.68–1.53)
Never CT/TT 1.07 (0.61–1.86) 1.57 (0.86–2.87) 0.87 (0.43–1.77)
Ever CT/TT 1.90 (1.14–3.16) 2.56 (1.47–4.46) 1.67 (0.91–3.06)
Additive interaction AP = 0.39 (95% CI -0.04 to 
+0.82); Padd
e = 0.08
AP = 0.24 (95% CI -0.26 to 
+0.75); Padd
e = 0.35
AP = 0.47 (95% CI -0.03 to 
+0.96); Padd
e = 0.07
Multiplicative interaction Pmulti
f = 0.20 Pmulti
f = 0.67 Pmulti
f = 0.18
Pack-years smoking
<10 CC 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
>10 CC 1.25 (0.89–1.75) 1.40 (0.96–2.05) 1.22 (0.81–1.83)
<10 CT/TT 1.09 (0.69–1.73) 1.48 (0.89–2.47) 1.00 (0.55–1.82)
>10 CT/TT 3.05 (1.64–5.66) 3.27 (1.74–6.15) 2.50 (1.25–5.00)
Additive interaction AP = 0.56 (95% CI 0.24 to 
0.88); Padd
e = 0.0006
AP = 0.42 (95% CI 0.01 to 
0.84); Padd
e = 0.04
AP = 0.51 (95% CI 0.09 to 
0.93); Padd
e = 0.02
Multiplicative interaction Pmulti
f = 0.04 Pmulti
f = 0.28 Pmulti
f = 0.13
Values are expressed as odds ratio (95% confidence interval). aConditional logistic regression, adjusting for parity, breast-feeding, menstrual 
irregularity, and age at menarche, menopausal status and postmenopausal hormone use. bUnconditional logistic regression adjusting for year of 
birth, parity, breast-feeding, menstrual irregularity, and age at menarche, menopausal status and postmenopausal hormone use. cRF-positive RA 
cases and all controls. dRF-negative RA cases and all controls. ePadd is the P value for attributable proportion (AP), one of the indices of additive 
interactions between binary smoking variable and binary PTPN22 genotype. fPmulti is the P value for multiplicative interaction term between binary 
smoking variable and binary PTPN22 genotype with one degree of freedom. NHS, Nurses' Health Study; RA, rheumatoid arthritis; RF, rheumatoid 
factor.Available online http://arthritis-research.com/content/10/3/R52
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NHS cheek cell DNA samples, we performed sensitivity anal-
yses with these samples excluded, and the interaction analy-
ses yielded similar and nonsignificant findings.)
Discussion
In these two cohorts of women followed prospectively for the
development of RA and for multiple potential environmental
exposures, we have confirmed that the R620W polymorphism
in the PTPN22 gene is associated with increased risk for RA.
We did not confirm that the PADI-4 (rs2240340) or the CTLA-
4 (rs3087243) polymorphism were associated with increased
risk for RA or for RF-positive RA in this population. We did not
find that cigarette smoking, parity, total duration of breastfeed-
ing, age at menarche, regularity of menses, menopausal status,
or postmenopausal hormone use – all associated with risk for
RA in past studies – were important confounders of the relation-
ships between these genotypes and RA. However, we did
uncover a significant multiplicative gene-environment interac-
tion between heavy smoking and PTPN22 in determining RA
risk.
The C→T polymorphism at position 1858 of the PTPN22 gene
interferes with the function of the PTPN22/Csk complex, which
is an important inhibitor of T-cell signaling, hindering its ability to
suppress T-cell activation [9,26,55]. Similar to past reports, we
have found the elevated risk to be primarily for RF-positive dis-
ease [9,25,56-58]. Several reports and a meta-analysis have
suggested that those with the PTPN22 risk allele have more
severe disease [25,57]. We have confirmed that a significant
association exists after adjustment for potential confounders,
including smoking and reproductive factors. We also found a
significant multiplicative interaction between heavy cigarette
smoking (≥10 pack-years) and the presence of the PTPN22 risk
allele, with a threefold elevated odds of developing RA in the
presence of both factors.
Kallberg and colleagues [38] recently explored potential gene-
environment and gene-gene interactions in RA susceptibility,
combining data from three large RA cohort studies. The results
of their study are slightly different from ours, in that they did not
find a significant interaction between the presence of the
PTPN22 polymorphism and smoking in determining RA risk.
Their gene-smoking interaction analyses used data from the
Swedish Environmental Investigations in RA incident RA cohort,
in which participants were asked to recall past smoking and
were classified as ever or never smokers. Using the detailed
prospective data regarding smoking amount and duration avail-
able for NHS and NHSII participants, we demonstrated a multi-
plicative interaction between the presence of the PTPN22 risk
allele and heavy cigarette smoking of ≥10 pack-years in this
female cohort. In past studies, we have found that the risk for RA
was significantly elevated with ≥10 pack-years [35]. Our results
now suggest that it may be necessary to exceed a threshold of
heavy smoking to trigger a biologic pathway in RA pathogenesis
involving the PTPN22 gene. Both HLA-SE and PTPN22 prima-
rily affect the risk for RF-positive and anti-CCP-positive RA
[25,36,59-61].
In the case of HLA-SE, it is hypothesized that cigarette smoking
leads to inflammation and citrullination of certain peptides,
which – when presented within the context of HLA-DR4 mole-
cules – are specifically recognized, contributing to anti-citrulline
autoimmunity [37]. The newly described interaction between
PTPN22 and heavy cigarette smoking suggests that the smok-
ing/citrullination/T-cell recognition and activation pathway in RA
pathogenesis may be influenced by both PTPN22 and HLA-
SE.
The CTLA-4 gene is an attractive candidate gene for RA sus-
ceptibility, given the role played by CTLA-4 (cytotoxic T-lym-
phocyte associated 4) in T-cell activation and that a CTLA-4-
IgG1 fusion protein is very effective in treating RA [62]. The
Table 7
PTPN22 genotype and HLA-SE interactions according to RF status in NHS/NHSII pooled samples
PTPN22 HLA-SE All casesa RF-positive casesb,c RF-negative casesb,d
CC None 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)
CC Any 1.97 (1.39–2.78) 2.37 (1.62–3.46) 1.33 (0.89–1.99)
T carrier None 1.41 (0.87–2.27) 1.76 (0.99–3.13) 1.40 (0.78–2.51)
T carrier Any 2.73 (1.55–4.81) 3.58 (2.02–6.35) 1.47 (0.74–2.92)
Additive interaction AP = 0.13 (95% CI -0.40 to +0.66); Padd
e = 
0.62
AP = 0.13 (95% CI -0.41 to +0.67); Padd
e = 
0.64e
AP = -0.18f
Multiplicative interaction Pmulti
g = 0.97g Pmulti
g = 0.72 Pmulti
g = 0.60
Values are expressed as odds ratio (95% confidence interval). aConditional logistic regression, adjusting for parity, pack-year smoking, breast-
feeding, menstrual irregularity, and age at menarche, menopausal status and postmenopausal hormone use. bUnconditional logistic regression 
adjusting for year of birth, parity, pack-year smoking, breast-feeding, menstrual irregularity, and age at menarche, menopausal status and 
postmenopausal hormone use. cRF-positive RA cases and all controls. dRF-negative RA cases and all controls. eP for AP, one of the indices of 
additive interactions between binary PTPN22 genotype and binary HLA-SE genotype. f95% confidence interval and P value for AP not applicable 
because of the negative estimate (antagonistic rather than synergistic). gP for multiplicative interaction term between binary PTPN22 genotype 
and binary HLA-SE genotype with one degree of freedom. AP, attributable proportion; NHS, Nurses' Health Study; RA, rheumatoid arthritis; RF, 
rheumatoid factor.Arthritis Research & Therapy    Vol 10 No 3    Costenbader et al.
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CT60 polymorphism was associated with a modest increase in
RA risk in the NHS cohort alone, and not in the NHSII cohort or
pooled results, possibly because of a lack of sufficient power to
detect a small elevation in risk (with OR in the order of 1.2)
reported in other studies [25]. In a post hoc power calculation,
for this CTLA-4 genotype with a risk allele frequency of 0.56
among controls and a two-sided type I error rate of 0.05, we had
71% power to detect an effect of 40% or greater (OR = 1.4).
The enzyme peptidylarginine deiminase-4, responsible for the
citrullination of peptides to which anti-CCP antibodies are
formed, is encoded by the PADI-4 gene. The PADI4_94 SNP
we have investigated was associated with RA in Japanese sub-
jects (OR = 1.97 [95% CI = 1.44 to 2.69]) [8]. The effect sizes
observed in previous replication studies in Caucasians have
been small (pooled OR = 1.1 [95% CI = 1.0 to 1.2]) [25,.64].
We were unable to detect an effect of this polymorphism on the
risk for RA in these cohorts of women, and this could reflect
inadequate power to detect a risk estimate of that magnitude.
Given that the allele frequencies in the controls were similar in
each of the cohorts to that reported in the literature, the signifi-
cant P value for heterogeneity across the cohorts we observed
was probably due to small sample size.
Limitations of this study that should be noted include the fact
that, in the NHS and NHSII cohorts, the presence or absence
of RF in the blood among RA cases was confirmed by medical
record review at diagnosis, and thus not assayed at the same
laboratory, and was not assayed in controls. Rheumatoid nod-
ules and radiographic erosions are likewise documented at the
time of diagnosis from thorough medical record review, but
cohort participants have not been followed longitudinally for RA
disease activity or complications. Similarly, we have limited data
in the medical record on antibodies to CCP among the cases,
which is important in the subphenotyping of RA [64], because
the dates of diagnosis for most of the RA cases in this cohort
preceded the clinical use of anti-CCP. Further analysis by anti-
CCP status could be potentially informative.
Although all participants included in this analysis were of self-
reported Caucasian ancestry, potential population stratification,
or confounding by ethnicity, still exists, in particular if the inclu-
sion of individuals of Northern compared with Southern Euro-
pean origin varied between cases and controls [48,65,66]. We
assessed the potential for this bias in two ways. First, we exam-
ined and did not find significant differences in the more precise
racial backgrounds reported by the Caucasian women included
as cases or controls in these analyses. Second, we genotyped
the lactase gene, which is known to exhibit substantial variation
in allele frequency from Northern to Southern Europe [47,48],
and found no significant differences in allele frequencies
between cases and controls. A recent whole-genome associa-
tion study investigating breast cancer risk alleles [67] found no
evidence of population stratification among self-reported Cau-
casian women in the NHS cohort.
This study is unique in that the participants were followed for
many years, in great detail, before the onset on their RA, and
environmental and reproductive risk factors for RA have been
well studied in this cohort [35,41]. This has allowed the investi-
gation of possible gene-environment interactions with each of
these recently described polymorphisms, and known and sus-
pected RA risk factors assessed prospectively, such as ciga-
rette smoking and menopausal status.
Conclusion
Our data confirm that the PTPN22 R620W polymorphism is a
strong risk factor for RF-positive RA, and that presence of this
polymorphism interacts with heavy cigarette smoking in a multi-
plicative manner. These findings contribute to the growing
understanding of how genetic and environmental factors inter-
act in RA pathogenesis, and suggest that heavy cigarette smok-
ing and PTPN22  may be acting in a similar mechanistic
pathway.
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